Carregant...
Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
Aberrant expression and/or activation of the MET receptor tyrosine kinase is characterized by genomic recombination, gene amplification, activating mutation, alternative exon-splicing, increased transcription, and their different combinations. These dysregulations serve as oncogenic determinants con...
Guardat en:
| Publicat a: | Ther Adv Med Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8020248/ https://ncbi.nlm.nih.gov/pubmed/33868463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211006957 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|